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Background: Visual impairment affects up to 70% of stroke survivors. We designed 
an app (StrokeVision) to facilitate screening for common post stroke visual issues 
(acuity, visual fields, and visual inattention). We sought to describe the test time, feasi-
bility, acceptability, and accuracy of our app-based digital visual assessments against 
(a) current methods used for bedside screening and (b) gold standard measures.
Methods: Patients were prospectively recruited from acute stroke settings. Index tests 
were app-based assessments of fields and inattention performed by a trained researcher. 
We compared against usual clinical screening practice of visual fields to confrontation, 
including inattention assessment (simultaneous stimuli). We also compared app to gold 
standard assessments of formal kinetic perimetry (Goldman or Octopus Visual Field 
Assessment); and pencil and paper-based tests of inattention (Albert’s, Star Cancelation, 
and Line Bisection). Results of inattention and field tests were adjudicated by a specialist 
Neuro-ophthalmologist. All assessors were masked to each other’s results. Participants 
and assessors graded acceptability using a bespoke scale that ranged from 0 (com-
pletely unacceptable) to 10 (perfect acceptability).
results: Of 48 stroke survivors recruited, the complete battery of index and reference 
tests for fields was successfully completed in 45. Similar acceptability scores were 
observed for app-based [assessor median score 10 (IQR: 9–10); patient 9 (IQR: 8–10)] 
and traditional bedside testing [assessor 10 (IQR: 9–10); patient 10 (IQR: 9–10)]. Median 
test time was longer for app-based testing [combined time to completion of all digital 
tests 420 s (IQR: 390–588)] when compared with conventional bedside testing [70 s, 
(IQR: 40–70)], but shorter than gold standard testing [1,260  s, (IQR: 1005–1,620)]. 
Compared with gold standard assessments, usual screening practice demonstrated 
79% sensitivity and 82% specificity for detection of a stroke-related field defect. This 
compares with 79% sensitivity and 88% specificity for StrokeVision digital assessment.
Conclusion: StrokeVision shows promise as a screening tool for visual complications 
in the acute phase of stroke. The app is at least as good as usual screening and offers 
other functionality that may make it attractive for use in acute stroke.
Clinical Trial registration: https://ClinicalTrials.gov/ct2/show/NCT02539381.
Keywords: apps, assessment, hemianopia, information technology, stroke, sensitivity, specificity, visual neglect
2Quinn et al. App for Assessing Stroke Visual Problems
Frontiers in Neurology | www.frontiersin.org March 2018 | Volume 9 | Article 146
inTrODUCTiOn
Visual impairment is reported to affect up to 66% of stroke sur-
vivors (1). Common visual deficits associated with stroke include 
visual field defects (hemianopia, quadrantanopia) (2), perceptual 
disorders (visual inattention/neglect) (3), and eye movement 
disorders (4). In a multicentre UK-based prospective cohort 
observation study of 915 patients, visual field loss was detected 
in 52.3% stroke survivors (2). A visual defect is a barrier to suc-
cessful rehabilitation after a stroke and is associated with a poorer 
prognosis for rehabilitation (5, 6) as well as a diminished quality 
of life (2, 7). As stroke is predominantly a disease of older adults, 
those affected by stroke may also have co-existing eye problems, 
such as cataract and macular degeneration.
The importance of stroke-related visual problems has been 
recognized in guidelines from various professional societies. 
For example, the National Advisory Committee for Stroke 
(NACS) in Scotland, the body responsible for implementing 
a national strategy on stroke, have produced guidance for 
the screening and assessment of patients in the acute phase: 
The Best Practice Statement (BPS) for Vision Problems after 
Stroke (8). This paper was written in collaboration with experts 
(multidisciplinary medical practitioners and academics), 
voluntary organizations, and patient representatives, and is a 
comprehensive review of current pathways and best practice in 
the acute assessment of stroke associated with visual problems. 
Although there is no internationally agreed approach to vision 
assessment in stroke, the 2013 BPS recommended: screening 
assessment of visual fields with confrontation for all patients 
with stroke; use of two tests for visual inattention/neglect; 
and that results of these assessments should be explained to 
patients and caregivers. There is evidence that these recom-
mendations are not universally adopted: Rowe et al. (9) in 2015 
reported that only around 50% of health professionals looking 
after stroke patients used validated tests to screen for visual 
problems.
Advances in technology can provide solutions in  situations 
where healthcare practice or delivery is not achieving desired 
standards. Mobile technology has become a ubiquitous part of 
modern life and has an increasing role in healthcare. Several 
studies have evaluated the physical properties of tablet devices 
(10, 11) with respect to visual assessment, evidencing a compara-
ble performance with contemporary clinical standards (12).
We developed an app-based tool (herein referred to as Stroke-
Vision) to try to meet the requirements of the BPS guidance, 
and improve stroke service performance in screening for visual 
impairment after a stroke (13). Our resource exploits the recent 
rapid advancements in mobile hardware and software to provide 
tools for assessment and education in stroke. The multimodality 
functioning has been developed by a multidisciplinary team of 
healthcare professionals, scientists, and engineers, and draws on 
the valuable input of patient and carer groups. In addition to the 
assessment function described in this paper, the app has educa-
tion and patient information materials. A unique feature of the 
app is that data from visual assessments can be used to simulate 
the visual problems experienced by the user through use of the 
tablet video camera.
In developing StrokeVision, our aim was to directly address 
the recommendations of the BPS, creating a screening resource 
that (a) provides a rapid and accurate assessment of gross visual 
deficits in stroke survivors, (b) can be used at the bedside by 
non-specialist staff at the acute stage, (c) provides a means 
of integrating the results into the patient’s electronic record, 
(d) provides clear information to patients and carers about the 
identified visual defects and their implications, and (e) har-
nesses the features of touchscreen computer technology to aid 
testing in stroke patients with concurrent morbidities, such as 
poor vision, decreased fine motor control, and comprehension 
difficulties.
An important aspect of the development of an app for clinical 
use is validation in the intended user group. In this paper, we 
describe our validation study of our StrokeVision app with a 
particular emphasis on accuracy of the app for detecting visual 
field and inattention issues.
MaTErialS anD METHODS
aims
Our primary aim was to validate visual assessments in stroke 
using our StrokeVision digital platform, including visual field 
assessments and visual inattention/neglect assessments.
We designed a series of analyses around accuracy and feasibi-
lity of testing. Primary questions of interest were:
1. How does a tablet-based digital visual field test (StrokeVision 
app) compare against traditional clinical assessment of visual 
fields in terms of:
a. Accuracy of app against visual confrontation (the standard 
screening test in stroke practice).
b. Accuracy of app against formal kinetic perimetry (the 
gold standard assessment in stroke practice: Goldmann or 
Octopus Perimetry).
c. Feasibility/acceptability of assessments (test completion).
d. Time taken to complete the test.
2. How do tablet-based digital inattention tests (StrokeVision 
app) compare against traditional clinical assessment of inat-
tention in terms of:
a. Accuracy of app against presentation of bilateral stimuli to 
confrontation (standard screen).
b. Accuracy of app against paper-based Line Bisection/Albert’s 
test (our chosen gold standards).
c. Feasibility/acceptability of assessments (test completion).
d. Time taken to complete the test.
Study Design
We conducted a prospective test accuracy study, recruiting 
patients from various acute stroke sites across a University 
Hospital stroke service. The protocol was registered and is avail-
able at clinical trials (NCT02539381). We followed Standard for 
Reporting Diagnostic Accuracy (STARD) best practice in design, 
conduct, and reporting of our study. Our project was approved by 
West of Scotland NHS Research Ethics (15/WS/0071) and local 
Research and Development. All subjects gave written informed 
FigUrE 1 | Tumbling E Near Acuity Test, adapted from the android-based 
distance optotype test, “peek acuity lite” (14.5). The patient is asked to swipe 
in the direction of the limbs of the E and a staircasing algorithm detects the 
threshold acuity level.
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consent in accordance with the Declaration of Helsinki. The work 
was supported by the NACS. The funder played no part in data 
collection, analysis, or interpretation.
All test data were recorded on specifically designed and 
piloted case report forms. Participants were assigned a unique 
identifier. For each participant, testing was performed on the 
same day.
Visual field testing was performed in a dedicated clinical area 
with availability of perimetry equipment (Goldmann or Octo-
pus). In contrast to white on white light projection into a Ganz-
feld dome, as employed in conventional kinetic perimetry, the 
digital targets emerging from the periphery were black on white. 
The size III (4 mm2) Goldmann stimulus was tested without cor-
rective lenses and standard lighting was used. We used standard 
operating procedures for transfer of patients from wards to 
the visual testing area and for testing. As many of the included 
patients had sustained, a recent stroke safety was a key concern. 
If the participant became fatigued or uncomfortable, testing was 
halted.
Participants
We recruited participants from two sites within NHS Greater 
Glasgow and Clyde, where visual assessment of stroke was 
routinely performed. Recruiting sites included adult stroke 
units and outpatient clinics. Recruitment ran from 23/7/2015 to 
28/6/2016.
The principal criterion for eligibility was clinical. We con-
sidered consecutive patients, where the attending clinical team 
requested formal assessment of vision, as we felt this was closest 
to how the app may be used in practice. Inclusion criteria were: 
clinical team felt suitable for assessment and requested assess-
ment of vision; patient able to provide informed consent. We 
excluded patients with no spoken English.
A senior clinician recorded basic clinical and demographic 
details of participants: age, sex, acuity, pathological stroke clas-
sification (ischemic or hemorrhagic), and time since stroke.
index Test
Our index test was the battery of vision tests within the Stroke-
Vision app. The app was used with a Google Nexus 10 tablet 
device (Google Inc., Mountain View, CA, USA). The vision tests 
within the app comprised:
•	 An assessment of visual acuity (digital Tumbling E visual acuity 
assessment at 33 cm, Figure 1). This test was an altered version 
of “peek acuity” prototype build, with the letter sizing re-set to 
a 33 cm working distance (in contrast to the cited validation 
which investigated a distance version of the application) (14).
•	 Visual field test results for right and left eyes (Figures 2A,B).
•	 Digital tests of visual inattention: line bisection (Figure  3A) 
and face cancelation (Figure 3B).
The app-based tests were performed by fully trained research 
assistants masked to other clinical and test data. Based on the 
field testing, the app produces a visual field map that has a similar 
format to the output from formal perimetry (Figure 2B). Based 
on the inattention tests, the app produces a screenshot of the 
completed task (Figure 2C). These raw data were shared with a 
senior neuro-ophthalmologist (GW), masked to other test data 
for final classification.
reference Standards
As the intention of the app is to complement initial screening 
assessment, rather than replace diagnostic assessment, our 
primary analysis compared the app to traditional clinical assess-
ment of visual field assessment using traditional confrontation, 
comprising a kinetic boundary test to moving fingers, where the 
patient reports when the examiner’s finger became visible when 
moved from outside peripheral vision of each quadrant toward 
fixation (from “unseen to seen”), comparing against the assessors 
own visual field.
Our screening test for visual inattention was also chosen to 
mirror routine clinical practice in the UK. We used bilateral 
visual stimuli (fingers moving) as the primary screen. Following 
assessment, the tester classified potential field deficit and 
recorded presence or absence of inattention, as is typical in clini-
cal practice. These assessments were performed by a fully trained 
clinician (Stroke Unit doctor at Registrar or Consultant level, 
or an Orthoptist with specialist stroke training) masked to all 
other clinical and test data. For those patients recruited from the 
orthoptist outpatient clinic, “both eyes open” confrontation was 
not part of usual assessment and so was not routinely recorded. 
This information was recorded in a standard data inclusion sheet, 
designed to reflect standard methods of recording in everyday 
practice.
To further describe the accuracy of the app, we also assessed 
against accepted “gold standards.” Our gold standard for field 
assessment was formal perimetry using Goldmann (Haag Streit, 
Berlin) or Octopus (Interzeag Octopus 500 EZ, Haag Streit, 
Berlin) visual field testing apparatus. Choice of assessment device 
was based on availability at the time of testing.
We recognize that many potential tests of visual inattention are 
available. We selected those tests that are used in specialist stroke 
vision clinics within our service and that are recommended in 
FigUrE 3 | (a) The Line Crossing test screen. Line thickness is calibrated 
against the acuity score to allow testing in low-vision patients. The patient is 
asked to press the perceived center of each line. (B) The Face Cancelation 
Test. A second test of inattention, whereby the patient is asked to press the 
small faces. As previous, line thickness is calibrated to acuity score.
FigUrE 2 | (a) The StrokeApp Visual Field test. The fixation target is the 
red nose of the smiling face graphic. The fixation target moves to the 
extreme corners of the device screen and the black circular target emerges 
from the periphery toward fixation. The peripheral target (black circle) 
subtends a similar angle to the Goldmann III target setting. The patient is 
encouraged to tap anywhere on the screen at the moment they detect the 
emerging peripheral target. The tester observes patient fixation, and if a 
fixation loss is detected, the screen is swiped to delete the previous input 
and re-test that point or quadrant. (B) The diagonal hashed lines indicate 
field defect once reaction time has been accounted for. The red line 
indicates limit of the visual field before reaction time has been accounted for. 
(C) StrokeSim. The detected perimetry plot is transposed as a digital filter to 
the feed from the device back-facing camera. The field within the defect is 
averaged to a single color.
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guidelines (8). Our gold standard assessment for visual inatten-
tion was a series of pencil and paper tests, including Albert’s test 
(15), and an object bisection (line bisection) test featuring six 
horizontal lines offset from the center drawn in a word document. 
These tests are used for formal assessment within our stroke 
service. All gold standard assessments were either performed by 
a senior orthoptist specializing in stroke, or a fully trained senior 
vision scientist (CT). Assessors had no access to medical notes 
detailing visual diagnoses. Where possible, assessors were masked 
to results of both app and screening assessments. In a small 
number of cases where assessors were unmasked, the data was 
not excluded. The raw data from the perimetry and inattention 
assessments were shared with a senior neuro-ophthalmologist 
(GW), masked to other test data for final classification.
Feasibility
To assess feasibility and acceptability of testing, we recorded 
the following metrics: time to complete each test; number of 
participants fully completing each test; and assessor perceived 
5Quinn et al. App for Assessing Stroke Visual Problems
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acceptability including patient compliance with test (recorded 
by the operator using a simple 0–10 scale, where 0 = completely 
unaccepatble and 10  =  perfect acceptability). After all three 
assessment methods were performed, participants were asked to 
quantify acceptability of each assessment using a simple 0–10 
scale, where 0  =  completely unacceptable and 10  =  perfect 
acceptability. Classification of assessment results: for the tradi-
tional testing (field and inattention performed at confrontation), 
classification was made at the point of testing by the examining 
clinician, and recorded on the data inclusion sheet, with the 
option of sketching any gross defect onto a four quadrant pro 
forma for each eye.
For the field maps produced by the app and formal perimetry, 
at the end of the data collection, order was randomized, and paired 
field test results (plots for right and left eyes) for (a) StrokeVision 
and (b) gold standard (Octopus or Goldmann) were presented 
to a Consultant Neuro-ophthalmologist (GW), who classified 
each pair as: (i) consistent with stroke-related defect; (ii) within 
normal limits; and (iii) non-gradable.
A free text field was included to allow further comment on 
the data arising from the app. Where a field plot was classified 
as “consistent with stroke-related defect,” the defect was sub-
classified according to predefined criteria: homonymous defect: 
hemianopia/quadrantanopia/macula sparing, etc.
For the inattention data, paper-based gold standard and digital 
inattention results were similarly randomized and presented to 
the Consultant Neuro-ophthalmologist (GW). For the digital 
assessments, these were presented as a screenshot of the com-
pleted test generated by StrokeVision. These results were again 
graded as: (i) consistent with inattention (sub-classified into right 
or left-sided); (ii) within normal limits; and (iii) non-gradable.
analyses
Our analysis was pilot in nature, however, to ensure we had 
sufficient data for validity testing, we performed an illustrative 
power calculation to inform our proposed sample size. Based on 
sensitivity of confrontation for detection of a perimetry deficit of 
0.5, and assuming the app will have a sensitivity of 0.7 (a value 
often taken as the minimum required for clinical utility) then at 
conventional alpha: 0.05 and beta: 0.2 we required a total of 50 
participants for paired comparisons. Sample size was calculated 
using the online StatsToDo program (Chinese University of 
Hong-Kong, 2014 www.statstodo.com).
We used simple descriptive statistics to characterize the 
participants. For feasibility data we calculated: the proportion of 
patients able to complete each assessment; median time of each 
assessment modality and median acceptability scores for assessor 
and patient. We assessed agreement between the three assessment 
approaches (usual screening practice, gold standard assessments, 
and StrokeVision) using standard metrics to describe “accuracy” 
(sensitivity; specificity; and predictive values). We created a series 
of contingency tables of frequencies for visual field and visual inat-
tention assessments against app and against each other. To allow 
further assessment of feasibility, we expanded the traditional “two 
by two” contingency tables with an intention to diagnose-based 
analyses that employed a third category of “unable to assess” for 
both index and reference tests, giving “3 ×  3” tables. Analyses 
were conducted by two assessors masked to other clinical details 
and to each other’s scores. Results were compared and final results 
were consensus.
rESUlTS
Participants
We recruited 48 participants. Median age was 63  years (IQR: 
54–72); n = 20 (42%) female; median visual acuity 0.2 logMAR 
(IQR: 0.1–0.4); median time from stroke 38 days (IQR: 7–99 days); 
n = 38 (80%) were ischemic infarcts and n = 15 (31%) of lesions 
were posterior cerebral territory. Of this group, 45 provided data 
that were used for accuracy based analyses (Table 1). According 
to gold standard assessment, 19 of 48 patients (39.6%) had field 
deficits and 3 (6.3%) had signs of visuospatial neglect.
Test accuracy
Comparing the app to standard visual screening and gold stand-
ards gave accuracy measures that would be in the range usually 
considered moderate to good for a clinical test and that were 
comparable to the performance of usual screening test against 
gold standard (Tables 1 and 2). Participants struggled to complete 
all the test battery; the lower number of patients contributing 
accuracy data on bilateral stimuli reflects that this assessment was 
not standard in those recruited from orthoptics outpatient clinics 
(Tables 1 and 2).
Feasibility/acceptability
Median time to complete app-based field assessments was 300 s 
(IQR: 300–468, range: 180–600); this was the longest component 
of the app test battery. Total test time for app was 420  s (IQR: 
390–588); compared with total test time of 70  s (IQR: 40–70) 
for screening tests and total test time 1,260 s (IQR: 1005–1620) 
for gold standard testing. Median assessor acceptability score 
for app-based field assessment was 10 (IQR: 8–10, range: 5–10), 
median patient acceptability score was 9 (IQR: 8–10, range: 5–10). 
Other metrics around acceptability and feasibility are presented 
in Table 3.
adverse Events
No serious adverse events were reported. One participant 
developed nausea during perimetry and further testing was 
abandoned, one patient fell en route to testing area and this 
participant’s data were not included in final analyses. Many par-
ticipants could not complete the full battery of screening, app, 
and gold standard assessments (see Tables  1 and 2). Reasons 
for test non-completion included difficulty in understanding 
instructions, difficulty in holding pen (for paper-based inatten-
tion tests), unable to position participant within the perimetry 
apparatus, fatigue.
DiSCUSSiOn
Significant variation exists in visual screening practices and 
provision for stroke-related visual problems (9). We assessed a 
novel tablet-based app designed to harmonize screening practices 
TaBlE 2 | Contingency table describing test positive and negative results for 
StrokeVision app versus standard confrontation (visual fields), third row and 
column describes where participants were untestable or did not complete 
testing.
Field  
deficit on 
app
no field 
deficit on 
app
no useable 
field data 
from app
Field deficit on confrontation 15 4 1
No field deficit on confrontation 6 20 1
No useable data from confrontation 2 0 0
TaBlE 1 | Test accuracy of Stroke Vision app compared to usual screening assessments for visual field deficits and visual inattention.
Comparison (a versus B) Total “useable” data Sensitivity (95% Ci) Specificity (95% Ci) PPV (95%Ci) nPV (95% Ci)
a B
App Visual fields confrontation 45 0.71 (0.48–0.89) 0.83 (0.64–0.95) 0.79 (0.54–0.94) 0.77 (0.56–0.91)
App Bilateral stimuli confrontation 28 0.67 (0.09–0.99) 0.88 (0.69–0.97) 0.40 (0.05–0.85) 0.96 (0.78–1.00)
App Formal perimetry 43 0.79 (0.54–0.94) 0.88 (0.68–0.97) 0.83 (0.59–0.97) 0.84 (0.64–0.95)
App Formal inattention 44 0.67 (0.09–0.99) 0.98 (0.87–1.00) 0.98 (0.87–1.00) 0.67 (0.09–0.99)
Visual fields to 
confrontation
Formal perimetry 42 0.79 (0.49–0.95) 0.82 (0.63–0.93) 0.69 (0.41–0.84) 0.88 (0.69–0.98)
Bilateral stimuli Formal inattention 26 0.50 (0.01–0.99) 0.87 (0.68–0.97) 0.25 (0.01–0.81) 0.95 (0.77–1.00)
App, StrokeVision app; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value.
Total useable data, where paired app and reference standard test data were available for a patient.
6
Quinn et al. App for Assessing Stroke Visual Problems
Frontiers in Neurology | www.frontiersin.org March 2018 | Volume 9 | Article 146
and reflect best practice. We compared the app to both standard 
clinical practice on the stroke ward and also the gold standard 
assessment in a tertiary referral neuro-ophthalmology center. 
Our test accuracy data suggest that the app performs reasonably 
well against both standard bedside screening tests and formal 
gold standard assessments. Our data around feasibility and 
acceptability suggest that patients with stroke were able to com-
plete app-based assessments and found this modality of testing 
to be acceptable.
The pattern of test accuracy data suggest that the app offers 
greater specificity than sensitivity. There is always a trade-off 
between sensitivity and specificity of a test, with no “optimal” 
value for these metrics, rather an evaluation of test properties 
should be made in light of the intended use of the test and the 
implications of a false positive and false negative results. For a 
screening tool, it may be more important to ensure that all cases 
are diagnosed and so higher sensitivity may be preferred. The 
sensitivity of both StrokeVision and confrontation in our data is 
higher than has been previously described for bedside “kinetic 
to finger” confrontation sensitivity, which has been reported at 
40% (95% CI 30–51) when performed by an ophthalmologist and 
compared with full threshold automated static perimetry (16). It 
should be noted, however, that our study had significant meth-
odological differences, with only stroke survivors being tested 
in our cohort (compared to a heterogeneous group of 138 eye 
clinic outpatients), and our gold standard being kinetic perimetry. 
While entrenched in clinical practice, and a basic competence 
trained and tested in medical school, confrontation field testing is 
performed in various ways, with significant technique-dependent 
variation in sensitivity reported. Our decision to use kinetic 
to finger confrontation is based on our impression of typical 
practice, though there is evidence that alternative techniques 
have increased sensitivity (16).
There are many approaches to the assessment of inattention, 
these include pencil and paper and electronic-based paradigms. 
There is no accepted, consensus on the preferred clinical assess-
ment for visual inattention. We chose those tests used in our 
clinical service as comparators, namely bilateral simultaneous 
confrontation as screening test and two paper-based assessments 
(Albert’s and line bisection) as gold standard. With this regards, 
we have an “imperfect” gold standard as both of the paper-based 
assessments which can produce false positives and false negatives 
compared to multidisciplinary clinical assessment of functional 
inattention.
Our aim was to describe accuracy against both usual screen-
ing practice and gold standard assessment. When interpreting 
the data on accuracy against kinetic finger confrontation and 
bilateral simultaneous confrontation it must be remembered that 
these tests are themselves imperfect. Where there was disagree-
ment between the app and the screening test, it is possible that 
the app was the true reflection of the patient’s visual status. It is 
reassuring that when tested against a gold standard the app was at 
least as good (and possibly improved upon) as the data obtained 
from simple screening tests.
The screening tests we used can only offer a basic assessment of 
inattention/field-defect present or absent. A potential advantage 
of the app is that it produces quantitative measures of inatten-
tion (laterality index) and fields (construction of a field map that 
emulates outputs from perimetry). We believe this more nuanced 
data offer greater clinical information than screening and could, 
in theory, be used to chart change over time in practice or in the 
setting of a clinical trial. Other potential pragmatic advantages 
not captured in the present research activity relate to compat-
ibility with the electronic patient record, and the ability to share 
results with patients, carers, and extended members of the 
multidisciplinary team. Designed for use in the NHS setting, 
reports can be cascaded via secure email. While confrontation 
techniques vary markedly between clinicians, standardization 
of such facets as screen contrast, target speed, together with 
automated calculation, and incorporation of reaction time, offer 
important advantages in terms of standardization and recording 
of visual field and inattention results. However, such potential 
advantages would need to be more robustly evaluated in a larger 
pragmatic trial. Limitations when compared to the gold standard 
TaBlE 3 | Feasibility and acceptability of the Stroke Vision app.
Median time to completion (seconds) Median acceptability score (assessor) Median acceptability score (patient)
App fields assessments 300 (IQR: 300–468, range: 180–600) 10 (IQR: 8–10, range: 5–10) 9 (IQR: 8–10, range: 5–10)
App shape cancelation 60 (IQR: 60–60, range: 30–300) 10 (IQR: 10–10, range: 7–10) 9 (IQR: 8–10, range: 6–10)
App line bisection 60 (IQR: 30–60, range: 20–300) 10 (IQR: 10–10, range: 7–10) 10 (IQR: 8–10, range: 3–10)
Formal perimetry 1,200 (IQR: 955–1500, range: 30–1,500) 8 (IQR: 5–10, range: 4–10) 7 (IQR: 5–10, range: 2–10)
Line bissection 30 (IQR: 25–60, range: 20–300) 8 (IQR: 10–10, range: 3–10) 10 (IQR: 8–10, range: 3–10)
Shape cancelation 30 (IQR: 20–60, range: 10–300) 10 (IQR: 9–10, range: 3–10) 9 (IQR: 8–10, range: 5–10)
Confrontation inattention 60 (IQR: 30–60, range: 20–300) 10 (IQR: 8–10, range: 5–10) 10 (IQR: 8–10, range: 4–10)
Screening inattention 10 (IQR: 10–10, range: 10–20) 10 (IQR: 10–10, range: 5–10) 10 (IQR: 9–10, range: 5–10)
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perimetry tests relate to the absence of chin and head rests, a 
single high contrast isopter being charted, smaller testable field, 
and less formal fixation monitoring.
As the Stroke Vision app was developed for use in clinical 
practice, we felt that demonstrating feasibility of testing was an 
important consideration. Our results show the difficulty of testing 
in an acute and subacute stroke population. Many participants 
struggled to complete the various screening, app-based, and 
gold standard assessments. Our quantitative assessments of user 
and tester acceptability are reassuring. For our bespoke, simple 
assessments of user and tester acceptability we did not perform 
formal comparative analyses. However, the basic descriptive 
statistics suggest that compliance and acceptability of the app are 
similar to current screening tools and possibly better than current 
gold standard assessments. Time required for app assessment 
is increased compared to usual screening, albeit the total time 
to complete the suite of app assessments is still relatively short 
(around 7 min) and would not preclude use of the app in a clinical 
setting.
The acuity test is the first assessment within StrokeVision, 
and serves as a prompt to ensure a near spectacle correction that 
is worn; it also provides a means to gauge the detection acuity 
at a typical reading distance (33  cm). This ensures subsequent 
assessments for a given eye are up-scaled appropriately, such that 
low acuity does not preclude assessment of field/inattention. This 
divergence in design, when compared to conventional standards, 
represents a source of variation, and a reason results may have 
been obtained with StrokeVision, but not with conventional 
bedside/gold standard methods. The strengths of our approach 
include a “real world” clinical study design that allows descrip-
tion of test properties in the healthcare context in which the app 
may be used. We used an “intention to diagnose” approach to 
quantifying (17) our accuracy assessments. This incorporates 
those instances, where testing was not possible or incomplete 
and highlights the inherent problems in test accuracy studies that 
involve participants with physical, visuospatial, and cognitive 
impairments (18). We also followed best practice in conduct and 
reporting using guidance for neuropsychological test accuracy 
studies (19). There are limitations to our approach. Although 
we based our sample size on a pre-specified power calculation, 
the wide confidence intervals around our accuracy measure sug-
gests a degree of uncertainty and a study with a greater number 
of participants would be preferred. Our real world sampling 
frame gave us a limited number of participants with inattention 
issues, and so the confidence intervals around these measures 
are particularly wide. A future test accuracy study may wish to 
“enrich” the sample with higher number of participants with 
suspected inattention issues.
Our data suggest that the app is at least as good as traditional 
bedside screening. One interpretation of these data would be that 
we should continue the status quo of screening using finger-based 
confrontation. Although not captured by our test metrics, the app 
offers other functionality that makes it potentially attractive for 
use in acute stroke settings. The app output offers a map of visual 
fields that allows a permanent visual record which can be stored 
and shared. The ability to chart fields at the bedside, rather than 
the patient having to move to an area with perimetry was appreci-
ated by patients and staff. The app offers more than diagnostic 
assessment and based on the results of testing, the app can link to 
information resources for patients and staff. A further feature that 
was particularly welcomed by patients is the ability of the app to 
use the assessment information to modify the images produced 
by the tablet’s camera and create a view of the world as the patient 
perceives it (e.g., with a field defect, etc).
There are other apps and software that have been developed to 
assess field deficits, but from a screen of app stores (at the time of 
writing) there are no commercially available apps with a stroke 
focus that assess acuity, fields, and inattention. The test proper-
ties of our app compare favorably with other apps and software 
available. A virtual reality test battery for assessing neglect has 
been developed (11), but is reliant on taking the patient to a 
computer and requires wearing virtual reality headset for the 
duration of the test—so while that test battery does address 
the need for digital assessments, it falls short of providing an 
easy-to-use bedside tool. A more portable computerized assess-
ment based on the BIT has been described and authors found 
their digital methods which were more objective and allowed 
for the collection of what they called “dynamic” data i.e., it was 
possible to gather information on the starting points and pat-
tern of cancelation in cancelation tasks (12). This may help in 
identifying subtle neglect and in exploring the heterogeneous 
nature of the condition (13).
We believe we have demonstrated proof of concept and suf-
ficient accuracy, feasibility, and acceptability to warrant further 
testing of the utility of StrokeVision. The next phase of testing 
would take an implementation science approach and address 
whether staff make use of the app, and whether this leads to 
improvements in care. This study focused on app-based patient 
assessments, however, the app offers other potential functional-
ity as an education, training, and information source and these 
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aspects would benefit from further assessment. Field deficits and 
inattention are only some of the stroke-related visual problems 
seen in practice. Further development of the app could be major 
on eye movement disorders using eye tracking software.
In conclusion, we have developed an app for assessment of 
stroke-related visual problems that has demonstrated acceptable 
test properties in a stroke population. The app is now ready for 
larger scale evaluation. We look forward to seeing the app being 
used in further assessments and welcome feedback from clini-
cians, patients, and other stake holders.
ETHiCS STaTEMEnT
Study Design: We conducted a prospective test accuracy study, 
recruiting patients from various acute stroke sites across a Uni-
versity Hospital stroke service. The protocol was registered and is 
available at clinical trials (NCT02539381). We followed Stand ard 
for Reporting Diagnostic Accuracy (STARD) best practice in 
design, conduct, and reporting of our study. Our project was 
approved by West of Scotland NHS Research Ethics (15/WS/0071) 
and local Research and Development. All subjects gave written 
informed consent in accordance with the Declaration of Helsinki. 
The work was supported by the National Advisory Committee 
for Stroke (NACS). The funder played no part in data collection, 
analysis, or interpretation.
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